Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Dynamic Hypermutation Status

NCT03519412 is registered in ClinicalTrials.gov with IFOM ETS - The AIRC Institute of Molecular Oncology as lead sponsor.

NCT NCT03519412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03519412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Dynamic Hypermutation Status
Lead sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2019
Completion date
January 8, 2025
Enrollment
107 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms, microsatellite instability